The current and future role of biomarkers in type 2 cytokine-mediated asthma management

Clinical and Experimental Allergy

Volumn 47, Issue 2, 2017, Pages 148-160

  Pavord, I D ^a   Afzalnia, S ^b   Menzies Gow, A ^c   Heaney, L G ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROCHE PRODUCTS LTD   (United Kingdom)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHITINASE 3 LIKE PROTEIN 1; CORTICOSTEROID; CYTOKINE; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN E; NITRIC OXIDE; TRANSCRIPTION FACTOR RUNX2; VOLATILE ORGANIC COMPOUND;

ASTHMA; CELL ACTIVATION; EOSINOPHIL COUNT; EXHALATION; EXPIRED AIR; HUMAN; INFLAMMATION; PRIORITY JOURNAL; REVIEW; TEMPERATURE MEASUREMENT; BLOOD; DISEASE MANAGEMENT; EOSINOPHIL; IMMUNOLOGY; LEUKOCYTE COUNT; METABOLISM; PATHOLOGY; RESPIRATORY SYSTEM; TH2 CELL;

ASTHMA; BIOMARKERS; CYTOKINES; DISEASE MANAGEMENT; EOSINOPHILS; EXHALATION; HUMANS; LEUKOCYTE COUNT; RESPIRATORY SYSTEM; TH2 CELLS;

EID: 85010877252     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12881     Document Type: Review

References (124)

1. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2016a. Available from: http://ginasthma.org/2016-gina-report-global-strategy-for-asthma-management-and-prevention/ (Last accessed 19 October 2016).
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention; Online Appendix, 2016b. Available from: http://ginasthma.org/2016-online-appendix-global-strategy-for-asthma-management-and-prevention/ (Last accessed 19 October 2016).
3. Asthma UK. Asthma facts and statistics. 2016. Available from: https://www.asthma.org.uk/about/media/facts-and-statistics/ (Last accessed 19 October 2016).
4. Holtzman MJ. Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. J Clin Invest 2012; 122:2741–8.
5. Barlow JL, McKenzie AN. Type-2 innate lymphoid cells in human allergic disease. Curr Opin Allergy Clin Immunol 2014; 14:397–403.
6. Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol 2015; 15:57–65.
7. Parulekar AD, Diamant Z, Hanania NA. Role of T2 inflammation biomarkers in severe asthma. Curr Opin Pulm Med 2016; 22:59–68.
8. Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can Respir J 2010; 17:e85–93.
9. Pavord ID, Brightling CE, Woltmann G, Wardlaw AJ. Non-eosinophilic corticosteroid unresponsive asthma. Lancet 1999; 353:2213–4.
10. Wenzel SE, Schwartz LB, Langmack EL et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160:1001–8.
11. Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715–21.
12. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218–24.
13. Haldar P, Brightling CE, Hargadon B et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973–84.
14. Perlikos F, Hillas G, Loukides S. Phenotyping and endotyping asthma based on biomarkers. Curr Top Med Chem 2016; 16:1582–6.
15. Bartminski G, Crossley M, Turcanu V. Novel biomarkers for asthma stratification and personalized therapy. Expert Rev Mol Diagn 2015; 15:415–30.
16. Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet 2015; 386:1086–96.
17. British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN). British guideline on the management of asthma – a national clinical guideline. 2014. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/ (Last accessed 19 October 2016).
18. Chung KF, Wenzel SE, Brozek JL et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343–73.
19. Hetherington KJ, Heaney LG. Drug therapies in severe asthma - the era of stratified medicine. Clin Med (Lond) 2015; 15:452–6.
20. O’Neill S, Sweeney J, Patterson CC et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. Thorax 2015; 70:376–8.
21. Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. Thorax 2012; 67:268–70.
22. Lindsay JT, Heaney LG. Nonadherence in difficult asthma - facts, myths, and a time to act. Patient Prefer Adherence 2013; 7:329–36.
23. Sweeney J, Patterson CC, Menzies-Gow A et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax 2016; 71:339–46.
24. Heaney LG, Djukanovic R, Woodcock A et al. Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax 2016; 71:187–9.
25. Vijverberg SJ, Hilvering B, Raaijmakers JA, Lammers JW, Maitland-van der Zee AH, Koenderman L. Clinical utility of asthma biomarkers: from bench to bedside. Biologics 2013; 7:199–210.
26. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69:89–95.
27. Arron JR, Choy DF, Scheerens H, Matthews JG. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc 2013; 10(Suppl):S206–13.
28. Fatemi F, Sadroddiny E, Gheibi A, Mohammadi Farsani T, Kardar GA. Biomolecular markers in assessment and treatment of asthma. Respirology 2014; 19:514–23.
29. Fitzpatrick AM. Biomarkers of asthma and allergic airway diseases. Ann Allergy Asthma Immunol 2015; 115:335–40.
30. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006; 11:54–61.
31. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171:912–30.
32. Scott M, Raza A, Karmaus W et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010; 65:258–62.
33. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Exhaled nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med 2005; 172:453–9.
34. Kupczyk M, ten Brinke A, Sterk PJ et al. Frequent exacerbators–a distinct phenotype of severe asthma. Clin Exp Allergy 2014; 44:212–21.
35. Hanania NA, Wenzel S, Rosén K et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804–11.
36. McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012; 186:1102–8.
37. Powell H, Murphy VE, Taylor DR et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378:983–90.
38. Abba AA. Exhaled nitric oxide in diagnosis and management of respiratory diseases. Ann Thorac Med 2009; 4:173–81.
39. National Institute for Health and Care Excellence (NICE). Diagnostic Guidance 12. Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath. NICE, 2014. Available from: http://www.nice.org.uk/guidance/dg12/resources/measuring-fractional-exhaled-nitric-oxide-concentration-in-asthma-niox-mino-niox-vero-and-nobreath-1053626430661 (Last accessed 19 October 2016).
40. Plaza V, Crespo A, Giner J et al. Inflammatory asthma phenotype discrimination using an electronic nose breath analyzer. J Investig Allergol Clin Immunol 2015; 25:431–7.
41. Broza YY, Haick H. Nanomaterial-based sensors for detection of disease by volatile organic compounds. Nanomedicine (Lond) 2013; 8:785–806.
42. Fens N, Roldaan AC, van der Schee MP et al. External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease. Clin Exp Allergy 2011; 41:1371–8.
43. van der Schee MP, Palmay R, Cowan JO, Taylor DR. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy 2013; 43:1217–25.
44. Dragonieri S, Schot R, Mertens BJ et al. An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007; 120:856–62.
45. Chiappori A, De Ferrari L, Folli C, Mauri P, Riccio AM, Canonica GW. Biomarkers and severe asthma: a critical appraisal. Clin Mol Allergy 2015; 13:20.
46. Kumar SD, Emery MJ, Atkins ND, Danta I, Wanner A. Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med 1998; 158:153–6.
47. García G, Bergna M, Uribe E, Yañez A, Soriano JB. Increased exhaled breath temperature in subjects with uncontrolled asthma. Int J Tuberc Lung Dis 2013; 17:969–72.
48. Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med 1975; 292:1152–5.
49. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2144–8.
50. Ortega HG, Liu MC, Pavord ID et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014; 371:1198–207.
51. Bel EH, Wenzel SE, Thompson PJ et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 2014; 371:1189–97.
52. Castro M, Wenzel SE, Bleecker ER et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2014; 2:879–90.
53. Nowak RM, Parker JM, Silverman RA et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med 2015; 33:14–20.
54. Park HS, Kim MK, Imai N et al. A Phase 2a study of benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol 2016; 169:135–45.
55. Castro M, Zangrilli J, Wechsler ME et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 2015; 3:355–66.
56. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest 2016; 150:799–810.
57. Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized Phase 3 study. Chest 2016; 150:789–98.
58. Corren J, Lemanske RF, Hanania NA et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088–98.
59. Otulana BA, Wenzel SE, Ind PW et al. A phase 2b study of inhaled pitrakinra, an IL-4/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma. Am J Respir Crit Care Med 2011; 183:A6179.
60. Luijk B, Lindemans CA, Kanters D et al. Gradual increase in priming of human eosinophils during extravasation from peripheral blood to the airways in response to allergen challenge. J Allergy Clin Immunol 2005; 115:997–1003.
61. Johansson MW, Barthel SR, Swenson CA et al. Eosinophil beta 1 integrin activation state correlates with asthma activity in a blind study of inhaled corticosteroid withdrawal. J Allergy Clin Immunol 2006; 117:1502–4.
62. Johansson MW. Activation states of blood eosinophils in asthma. Clin Exp Allergy 2014; 44:482–98.
63. Woodruff PG, Modrek B, Choy DF et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388–95.
64. St Ledger K, Agee SJ, Kasaian MT et al. Analytical validation of a highly sensitive microparticle-based immunoassay for the quantitation of IL-13 in human serum using the Erenna immunoassay system. J Immunol Methods 2009; 350:161–70.
65. Takayama G, Arima K, Kanaji T et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006; 118:98–104.
66. Woodruff PG, Boushey HA, Dolganov GM et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104:15858–63.
67. Blanchard C, Mingler MK, McBride M et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 2008; 1:289–96.
68. Sehra S, Yao W, Nguyen ET et al. Periostin regulates goblet cell metaplasia in a model of allergic airway inflammation. J Immunol 2011; 186:4959–66.
69. Sidhu SS, Yuan S, Innes AL et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci USA 2010; 107:14170–5.
70. Jia G, Erickson RW, Choy DF et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130:647–54.
71. Wagener AH, de Nijs SB, Lutter R et al. External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015; 70:115–20.
72. Matsumoto H. Serum periostin: a novel biomarker for asthma management. Allergol Int 2014; 63:153–60.
73. Kato G, Takahashi K, Izuhara K, Komiya K, Kimura S, Hayashi S. Markers that can reflect asthmatic activity before and after reduction of inhaled corticosteroids: a pilot study. Biomark Insights 2013; 8:97–105.
74. Kanemitsu Y, Matsumoto H, Izuhara K et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013; 132:305–12.
75. Izuhara K, Matsumoto H, Ohta S, Ono J, Arima K, Ogawa M. Recent developments regarding periostin in bronchial asthma. Allergol Int 2015; 64(Suppl):S3–10.
76. Hanania NA, Noonan M, Corren J et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 2015; 70:748–56.
77. Brightling CE, Chanez P, Leigh R et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3:692–701.
78. Genentech press release, February 2016. Available from: http://www.gene.com/media/press-releases/14619/2016-02-28/genentech-provides-update-on-two-identic (Last accessed 19 October 2016).
79. Sen K, Lindenmeyer MT, Gaspert A et al. Periostin is induced in glomerular injury and expressed de novo in interstitial renal fibrosis. Am J Pathol 2011; 179:1756–67.
80. Bonnet N, Garnero P, Ferrari S. Periostin action in bone. Mol Cell Endocrinol 2016; 432:75–82.
81. Qin X, Yan M, Zhang J et al. TGFβ3-mediated induction of periostin facilitates head and neck cancer growth and is associated with metastasis. Sci Rep 2016; 6:20587.
82. Chupp GL, Lee CG, Jarjour N et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007; 357:2016–27.
83. Tang H, Fang Z, Sun Y et al. YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J 2010; 35:757–60.
84. Konradsen JR, James A, Nordlund B et al. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol 2013; 132:328–35.
85. Specjalski K, Jassem E. YKL-40 protein is a marker of asthma. J Asthma 2011; 48:767–72.
86. Ober C, Tan Z, Sun Y et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008; 358:1682–91.
87. Hinks TS, Brown T, Lau LC et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol 2016; 138:61–75.
88. Ozyigit LP, Morita H, Akdis M. Innate lymphocyte cells in asthma phenotypes. Clin Transl Allergy 2015; 5:23.
89. Liu T, Wu J, Zhao J et al. Type 2 innate lymphoid cells: a novel biomarker of eosinophilic airway inflammation in patients with mild to moderate asthma. Respir Med 2015; 109:1391–6.
90. Szefler SJ, Wenzel S, Brown R et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012; 129(3 Suppl):S9–23.
91. Bousquet J, Rabe K, Humbert M et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101:1483–92.
92. Wahn U, Martin C, Freeman P, Blogg M, Jimenez P. Relationship between pretreatment specific IgE and the response to omalizumab therapy. Allergy 2009; 64:1780–7.
93. Diamant Z, Tufvesson E, Bjermer L. Which biomarkers are effective for identifying Th2-driven inflammation in asthma? Curr Allergy Asthma Rep 2013; 13:477–86.
94. Peona V, De Amici M, Quaglini S et al. Serum eosinophilic cationic protein: is there a role in respiratory disorders? J Asthma 2010; 47:131–4.
95. Koh GC, Shek LP, Goh DY, Van Bever H, Koh DS. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med 2007; 101:696–705.
96. Jahnz-Róyk K, Plusa T, Mierzejewska J. Eotaxin in serum of patients with asthma or chronic obstructive pulmonary disease: relationship with eosinophil cationic protein and lung function. Mediators Inflamm 2000; 9:175–9.
97. Hoffmann HJ, Nielsen LP, Harving H, Heinig JH, Dahl R. Asthmatics able to step down from inhaled corticosteroid treatment without loss of asthma control have low serum eotaxin/CCL11. Clin Respir J 2008; 2:149–57.
98. Shiobara T, Chibana K, Watanabe T et al. Dipeptidyl peptidase-4 is highly expressed in bronchial epithelial cells of untreated asthma and it increases cell proliferation along with fibronectin production in airway constitutive cells. Respir Res 2016; 17:28.
99. Saad-El-Din Bessa S, Abo El-Magd GH, Mabrouk MM. Serum chemokines RANTES and monocyte chemoattractant protein-1 in Egyptian patients with atopic asthma: relationship to disease severity. Arch Med Res 2012; 43:36–41.
100. Zhao JJ, Yang L, Zhao FQ, Shi SM, Tan P. Osteopontin levels are elevated in patients with asthma. J Int Med Res 2011; 39:1402–7.
101. Akelma AZ, Cizmeci MN, Kanburoglu MK et al. Elevated level of serum osteopontin in school-age children with asthma. Allergol Immunopathol (Madr) 2014; 42:275–81.
102. Sekiya T, Yamada H, Yamaguchi M et al. Increased levels of a TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 2002; 57:173–7.
103. Hijnen D, De Bruin-Weller M, Oosting B et al. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis. J Allergy Clin Immunol 2004; 113:334–40.
104. Toru Ü, Ayada C, Genç O et al. Visfatin and ghrelin: can they be forthcoming biomarkers or new drug targets for asthma? Int J Clin Exp Med 2015; 8:6257–61.
105. Patil SP, Wisnivesky JP, Busse PJ, Halm EA, Li XM. Detection of immunological biomarkers correlated with asthma control and quality of life measurements in sera from chronic asthmatic patients. Ann Allergy Asthma Immunol 2011; 106:205–13.
106. Li Y, Hua S. Mechanisms of pathogenesis in allergic asthma: role of interleukin-23. Respirology 2014; 19:663–9.
107. Ciprandi G, Cuppari C, Salpietro AM et al. Serum IL-23 strongly and inversely correlates with FEV1 in asthmatic children. Int Arch Allergy Immunol 2012; 159:183–6.
108. Verrills NM, Irwin JA, He XY et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1633–43.
109. Abdel Fattah M, El Baz M, Sherif A, Adel A. Complement components (C3, C4) as inflammatory markers in asthma. Indian J Pediatr 2010; 77:771–3.
110. Mosca T, Menezes MC, Dionigi PC, Stirbulov R, Forte WC. C3 and C4 complement system components as biomarkers in the intermittent atopic asthma diagnosis. J Pediatr (Rio J) 2011; 87:512–6.
111. Tartibi HM, Bahna SL. Clinical and biological markers of asthma control. Expert Rev Clin Immunol 2014; 10:1453–61.
112. Ramirez D, Patel P, Casillas A, Cotelingam J, Boggs P, Bahna SL. Assessment of high-sensitivity C-reactive protein as a marker of airway inflammation in asthma. Ann Allergy Asthma Immunol 2010; 104:485–9.
113. Fujita M, Ueki S, Ito W et al. C-reactive protein levels in the serum of asthmatic patients. Ann Allergy Asthma Immunol 2007; 99:48–53.
114. Qian FH, Zhang Q, Zhou LF et al. High-sensitivity C-reactive protein: a predicative marker in severe asthma. Respirology 2008; 13:664–9.
115. Sackmann EK, Berthier E, Schwantes EA et al. Characterizing asthma from a drop of blood using neutrophil chemotaxis. Proc Natl Acad Sci USA 2014; 111:5813–8.
116. European Lung Foundation. U-BIOPRED. 2013. Available from: http://www.europeanlung.org/en/projects-and-research/projects/u-biopred/home (Last accessed 19 October 2016).
117. Thomson NC. Novel approaches to the management of noneosinophilic asthma. Ther Adv Respir Dis 2016; 10:211–34.
118. Panettieri RA Jr. Neutrophilic and pauci-immune phenotypes in severe asthma. Immunol Allergy Clin North Am 2016; 36:569–79.
119. Chung KF. Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. J Intern Med 2016; 279:192–204.
120. Busse WW, Holgate S, Kerwin E et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013; 188:1294–302.
121. O’Byrne PM, Metev H, Puu M et al. Efficacy and safety of a CXCR2 antagonist, AZD5069, in patients with uncontrolled persistent asthma: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2016; 4:797–806.
122. Pavord ID, Shaw DE, Gibson PG, Taylor DR. Inflammometry to assess airway diseases. Lancet 2008; 372:1017–9.
123. Pavord ID, Agusti A. Blood eosinophil count: a biomarker of an important treatable trait in patients with airway disease. Eur Respir J 2016; 47:1299–303.
124. Agusti A, Bel E, Thomas M et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 2016; 47:410–9.